We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elanco Animal Health (ELAN) Surges 7.6%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Elanco Animal Health Incorporated (ELAN - Free Report) shares soared 7.6% in the last trading session to close at $25.18. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sharp rise in ELAN shares can be attributed to the company’s strong fourth-quarter performance and encouraging forward outlook, which reinforced confidence in its ongoing turnaround. Elanco reported a modest earnings beat alongside solid revenue growth, reflecting improving operational execution and steady demand across its core segments. More importantly, management issued constructive 2026 guidance, calling for continued revenue growth and stronger EBITDA expansion supported by margin improvement initiatives and cost efficiencies. This update signaled a clearer path to sustained profitability, strengthening investor sentiment around Elanco’s long-term growth trajectory.
This company is expected to post quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of -5.4%. Revenues are expected to be $1.28 billion, up 7.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Elanco Animal Health, the consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ELAN going forward to see if this recent jump can turn into more strength down the road.
Elanco Animal Health is part of the Zacks Medical - Outpatient and Home Healthcare industry. Quest Diagnostics (DGX - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $198.61. DGX has returned -3.8% in the past month.
Quest Diagnostics' consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $2.39. Compared to the company's year-ago EPS, this represents a change of +8.1%. Quest Diagnostics currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Elanco Animal Health (ELAN) Surges 7.6%: Is This an Indication of Further Gains?
Elanco Animal Health Incorporated (ELAN - Free Report) shares soared 7.6% in the last trading session to close at $25.18. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sharp rise in ELAN shares can be attributed to the company’s strong fourth-quarter performance and encouraging forward outlook, which reinforced confidence in its ongoing turnaround. Elanco reported a modest earnings beat alongside solid revenue growth, reflecting improving operational execution and steady demand across its core segments. More importantly, management issued constructive 2026 guidance, calling for continued revenue growth and stronger EBITDA expansion supported by margin improvement initiatives and cost efficiencies. This update signaled a clearer path to sustained profitability, strengthening investor sentiment around Elanco’s long-term growth trajectory.
This company is expected to post quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of -5.4%. Revenues are expected to be $1.28 billion, up 7.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Elanco Animal Health, the consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ELAN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Elanco Animal Health is part of the Zacks Medical - Outpatient and Home Healthcare industry. Quest Diagnostics (DGX - Free Report) , another stock in the same industry, closed the last trading session 0.2% lower at $198.61. DGX has returned -3.8% in the past month.
Quest Diagnostics' consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $2.39. Compared to the company's year-ago EPS, this represents a change of +8.1%. Quest Diagnostics currently boasts a Zacks Rank of #3 (Hold).